remodeling

GS-6201 (CVT-6883) is a selective antagonist of the adenosine A2B receptor, demonstrating high affinity and selectivity with a Ki of 22 nM for human adenosine A2B receptors.

GFB-8438 is a potent and subtype selective inhibitor of TRPC5(IC50s of 0.18 and 0.29 μM of hTRPC5 and hTRPC4, respectively).

SB 204741 is a selective 5-HT2B antagonist with high affinity and pKi value of 7.1.

JQ-1 (carboxylic acid) is a cell-permeable BRD4 inhibitor with IC50s of 77 nM for BRD4(1) and 33 nM for BRD4(2)

TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain to interfere with its homodimerization and suppress MyD88 signaling. TJ-M2010-5 can be used in myocardial [ischemia/reperfusion] injury studies.

ATP (Adenosine triphosphate) provides cellular energy, participates in overall energy balance, and maintains intracellular homeostasis. ATP can act as an extracellular signaling molecule through interactions with specific purinergic receptors to mediate a variety of processes including neurotransmission, inflammation, apoptosis, and bone remodeling.

Rho-Kinase-IN-1 is an inhibitor of ROCK with Kis of 30.5 nM and 3.9 nM for ROCK1 and ROCK2, respectively. Rho-Kinase-IN-1 can be used in studies about excessive cell proliferation, remodeling, edema and inflammation diseases.

N-Oleoyl-L-Serine (N-Oleoylserine) is an endogenous long-chain fatty acid amide that is a lipid modulator of bone remodeling and stimulates osteoclast apoptosis which can be used to study osteoporosis. N-Oleoyl-L-Serine showed high activity in an osteoblast proliferation assay.N-Oleoyl-L-Serine promotes osteoclast apoptosis by inhibiting Erk1/2 phosphorylation and expression of nuclear κB ligand (RANKL) receptor activator in bone marrow stromal cells and osteoblasts, which attenuates osteoclast populations.

5-Hydroxy-1-methylhydantoin (HD-003) is an antioxidant potentially for the treatment of renal failure. A creatinine metabolite, 5-Hydroxy-1-methylhydantoin , a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. 5-Hydroxy-1-methylhydantoin is a novel anti-oxidant drug completely suppressed the expression of B2-kinin receptors (B2KR) in response to high glucose (25 mM) stimulation in VSMC and was also shown to attenuate the effects of BK on VSMC remodeling. 5-Hydroxy-1-methylhydantoin inhibited the BK-induced increase in MAPK phosphorylation and attenuated the increase in connective tissue growth factor (CTGF) protein levels in VSMC. These findings suggest that 5-Hydroxy-1-methylhydantoin may confer vascular protection against high glucose concentrations and BK-stimulation to ameliorate vascular injury and remodeling through its anti-oxidant properties.

Myoseverin, an inducer of the reversible fission of multinucleated myotubes into mononucleated fragments, affecting the expression of a variety of growth factor, immunomodulatory, extracellular matrix-remodeling, and stress response genes, consistent with

Manitimus (FK778) is an inhibitor of dehydroorotate dehydrogenase and an immunosuppressant with immunosuppressive and antiproliferative activity, prevents vascular remodeling after mechanical endothelial injury, and can be used to study immune dysfunction.

XL-784 is a selective inhibitor of matrix metalloproteinases (MMPs) with IC50 values of approximately 1900, 0.81, 120, 10.8, 18, and 0.56 nM for MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, and MMP-13, respectively. XL-784 demonstrates potential in a broad range of cancer research applications due to its capability to modulate extracellular matrix remodeling, tumor invasion, and metastasis.

XRK3F2 is an inhibitor of the p62-ZZ domain, blunts MM-induced Runx2 suppression in vitro, and induces new bone formation and remodeling in the presence of tumor in vivo.

VZ185 is a potent, fast-acting, and selective von Hippel–Lindau–based dual degrader probe targeting BRD9 and BRD7 with DC50 values of 4.5 nM and 1.8 nM, respectively. VZ185 displays marked cytotoxicity in EOL-1 and A-402 cell lines with EC50 values of 3 nM and 40 nM, enabling advanced studies of chromatin remodeling, targeted protein degradation, and cancer cell dependency on SWI/SNF complex components.

Nedocromil sodium is a pharmacologic stabilizer of mast cells, has been shown to normalize cytokine levels and attenuate cardiac remodeling.

Enrasentan (also known as SB-217242) is a dual receptor endothelin antagonist with a higher affinity for the ET(A) receptor. In animal models of hypertension and cardiac hypertrophy, this compound reduces blood pressure, prevents cardiac hypertrophy, and preserves myocardial function. Enrasentan enhances survival rates, limits left ventricular remodeling, and maintains myocardial performance in hypertensive cardiac hypertrophy and dysfunction.

Tetradifon is a broad-spectrum organochlorine acaricide insecticide and a potent inhibitor of the mitochondrial oligomycin sensitivity conferring protein (OSCP)，a subunit of ATP synthase. Tetradifon is utilized for controlling a variety of mite pests and inhibiting energy-related mitochondrial activities including ADP-stimulated respiration and ATPase activity with an IC50 range of 4.5-27 nmoL/mg mitochondrial protein; it exerts oligomycin-like effects by inhibiting oxidative phosphorylation, inducing significant oxidative stress, and interfering with bone metabolism, making it a compound of interest for researching mitochondrial function, bone remodeling mechanisms, and nephrotoxicity.

PDE10A-IN-5 (Compound A30) is an orally active inhibitor of phosphodiesterase 10A (PDE10A) with an IC50 value of 3.5 nM. By inhibiting PDE10A, it activates the cyclic adenosine monophosphate (cAMP)-related signaling pathway, exhibiting activity against pulmonary vascular remodeling. This compound is applicable to research in the field of pulmonary arterial hypertension.

E7130 is a microtubule inhibitor that enhances the tumor microenvironment by inhibiting cancer-associated fibroblasts and facilitating the remodeling of the tumor vasculature system.

AH001 is an orally active compound that binds to a concealed pocket near GDP within RhoA, exhibiting a binding affinity of 73.16 nM. By interacting with GDP, AH001 stabilizes the interaction between RhoA and its endogenous inhibitor, RhoGDIα. This compound reduces nuclear translocation of downstream MRTFA and downregulates fibrosis/hypertrophy-related proteins. AH001 alleviates myocardial remodeling in various heart failure animal models and 3D cardiac tissue models. Its cardioprotective effects are mediated through the RhoA-RhoGDIα axis, effectively inhibiting downstream RhoA activation signals.

LIBX-A403 (Compound 21) is a highly selective inhibitor of acyl-CoA synthetase long-chain family member 4 (ACSL4) with an IC50 of 0.049 μM. It prevents ACSL4-mediated pro-ferroptotic phospholipid remodeling. LIBX-A403 shows potential for research in cancer, such as triple-negative breast cancer, and neurodegenerative disorders like Parkinson's disease.

Opitor-0 is a highly selective OPA1 GTPase inhibitor with an IC₅₀ of 3 μM. Opitor-0 disrupts the stability of OPA1 oligomers, triggering mitochondrial cristae remodeling and fragmentation, which leads to massive release of cytochrome c and subsequently induces apoptosis. In anticancer studies, Opitor-0 has been shown to exhibit synergistic effects when combined with the Bcl-2 inhibitor ABT-737 or Venetoclax.

Zaprinast is a cGMP-selective phosphodiesterase (PDE) inhibitor and a GPR35 agonist. It has a strong activating effect on rat GPR35 and a certain activating effect on human GPR35. It reduces vascular remodeling through anti-proliferative and pro-apoptotic effects.

Y1693 is an orally active RANKL inhibitor with a Kd value of 5.03 μM for hRANKL. Y1693 inhibits activation of the downstream c-fos/NFATc1 signaling pathway by blocking the interaction between RANKL and RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation, and bone resorptive activity while downregulating the mRNA and protein expression levels of TRAP, cathepsin K, c-fos, and NFATc1. Y1693 demonstrates no obvious cytotoxicity toward bone marrow-derived macrophages and osteoclast precursor cells and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research involving osteoporosis, osteoclast biology, and periodontal disease-associated bone remodeling mechanisms.